Articles tagged with Drug Studies
A phase 3 clinical trial demonstrated tirzepatide's effectiveness in achieving an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or overweight comorbidities. Participants who received tirzepatide achieved a total mean weight loss of 26.6%, compared to 3.8% for those on placebo.
The ATLANTIS trial found that amitriptyline significantly improved IBS symptoms, with participants taking the medication reporting a bigger improvement in symptom scores after six months. The medication was well-tolerated and showed no significant impact on anxiety or depression scores.
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
A new trial combining an Alzheimer's medication with two other drugs may amplify its effects and arrest disease progression. The trial, funded by a $150M grant, will recruit 900 participants with early-onset Alzheimer's.
A study by researchers from National Institutes of Health and Glasgow University found that amlodipine does not activate calcium channels, contradicting earlier concerns. The medication remains a recommended first-line treatment for high blood pressure, reducing deaths from hypertension.
TTUHSC researchers received funding for pilot studies on photothermal tumor therapy, clear cell renal cell carcinoma, and colorectal cancer screening in underserved areas. The grants support the purchase of a cell sorter and address regional health disparities.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A new study shows that XEN1101 can reduce seizure frequency by more than 50% in some patients and sometimes eliminate seizures altogether. The medication, a potassium-channel opener, boosts the flow of potassium out of nerves to stop them from firing.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
A large epidemiological study found a higher incidence of stomach paralysis, pancreatitis, and bowel obstruction in patients taking GLP-1 agonist medications for weight loss. The study, published in JAMA, highlights the need for updated warning labels to inform patients of these potential risks.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Researchers at Northwestern University developed Lattice, a device that simulates human disease in multiple organs to analyze interactions and test new drugs. The technology can replicate complex disease processes, allowing scientists to study the effects of obesity on endometrial cancer, for example.
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers found that MDMA increased feelings of connection and oxytocin levels in volunteers, while methamphetamine also showed similar effects. These findings suggest potential therapeutic benefits for traditional talk therapy.
Researchers at UVA Health System have developed a powerful new tool to understand how medications affect men and women differently. The model has provided unprecedented insights into biological processes in the liver, helping ensure that new medications will not cause harmful side effects.
A new editorial paper highlights the importance of including older patients in lung cancer clinical trials, where they are often undertreated due to age-related factors. The paper emphasizes the need for increased collaboration among stakeholders to enhance enrollment and retention of older cancer patients.
Researchers found that etripamil nasal spray restored normal heart rhythms within 30 minutes in 54% of patients, making it a potential new option for self-treating paroxysmal supraventricular tachycardia. The study showed the medication to be safe and well-tolerated.
A significant increase in the need for treatment of eye diseases is expected due to the growing elderly population. The number of patients requiring anti-VEGF medication is projected to rise by 50% over the next five years.
Researchers developed a computational model to analyze glucose-responsive insulin (GRI) performance in human patients. The model predicted that differences in sugar receptor behavior between humans and lab animals led to the drug's poor effect in clinical trials. This breakthrough helps researchers design better GRIs, potentially reduc...
A new health care utility model called Civica Rx increases supply security and reduces costs for health systems, with increased access to critical medications. The model prioritizes access over profit and offers transparent pricing for all customers.
A clinical trial has shown that methotrexate is a useful and safe treatment for children with severe atopic dermatitis, offering better objective disease control compared to ciclosporin. The study found no concerning safety signals, making methotrexate an attractive alternative for patients in settings where healthcare resources are li...
Researchers found that patients prescribed amoxicillin-clavulanate had higher rates of gastrointestinal symptoms and yeast infections than those prescribed amoxicillin. The study showed no difference in treatment failure rates between the two antibiotics, with treatment failure occurring in less than 2% of cases.
A large international study led by Danish researchers may have brought us closer to a cure for HIV. The study found that patients who received monoclonal antibodies before pausing their regular treatment experienced a period of virus suppression, and some even saw their immune system partially or completely suppress the virus.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
Patients with stage 1-3 non-small cell lung cancer treated with combination immunotherapy before surgery had a better major pathological response rate than those receiving single-agent therapy alone. The NeoCOAST platform trial found that targeting multiple cancer pathways through therapy may be superior to a single treatment.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
The collaboration has garnered $5.68 million of grant support, with a five-year $2.13 million National Institutes of Health R01 grant and a five-year $2.89 million NIH R01 grant. Researchers are using computational biology to model a key Alzheimer's protein called TREM2 and its interactions with small chemical molecules.
A new computational approach removes movement in heart cell and tissue images, allowing direct monitoring of electro-mechanical coupling. The algorithm mimics a drug's action, giving insight into heart diseases.
Researchers at Pritzker Molecular Engineering have developed an 'inverse vaccine' that can eliminate autoimmune reactions associated with multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. The vaccine works by removing the immune system's memory of a molecule, allowing it to tolerate healthy tissues.
Researchers at University of Tsukuba found that aripiprazole modulates the mammalian central circadian clock by disrupting synchronization among clock neurons and enhancing responsiveness to light stimuli in mice. This discovery expands the potential clinical usage of aripiprazole as a treatment for circadian rhythm sleep disorders.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers have developed a device that can be implanted into tumors during surgery to test new treatments, providing unprecedented insight into the effects of drugs on glioma tumors. The device, which is designed to be used during standard of care surgery, caused no adverse effects on patients in a phase 1 clinical trial.
Johns Hopkins Medicine will improve clinical trial efficiency and quality with a $24.5M grant, reducing startup time by up to 50% and enhancing participant engagement. The Trial Innovation Center will develop new methods for multicenter trials, including AI-enhanced patient screening and gamification.
A new opinion piece highlights the safety gap in clinical trials and drug labeling for people with obesity, arguing that correct dosing instructions should be included on labels. The authors recommend a three-pronged approach to address this gap, including conducting studies in people with obesity before market approval.
A nationally representative study found that at least one out of five prescriptions for commonly prescribed generic medications were cheaper through Amazon Prime or GoodRx Gold discount cards compared to actual out-of-pocket payments made by patients. The findings highlight the disproportionately higher frequency of out-of-pocket payme...
A new study reveals that red blood cells can protect against myocardial infarction when exposed to oxygen deficiency, and this effect is enhanced by a nitrate-rich diet. The research provides hope for patients at risk of heart disease.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
Two studies demonstrate that artificial intelligence in colonoscopy can increase adenoma detection rates and reduce miss rates, but also lead to increased removal of non-neoplastic polyps. The findings suggest the need for additional research on more defined detection parameters before AI can be integrated into routine clinical care.
A new clinical study found that adjuvant treatment with Mitotane is not necessary for patients with low risk of recurrence if they have a complete R0 resection, low tumour stage and Ki-67 levels below 10%. This approach has shown no significant improvement in relapse rate but is associated with side effects.
A recent study found that the FDA approved 65% of novel drugs in 2022 based on a single clinical trial, while only half of the available studies were classified as randomized clinical trials. This lack of transparency raises concerns about the completeness of the approval process and patient access to accurate information.
Researchers at the University of Minnesota Medical School have successfully tested a new oral antifungal therapy, Lipid Nanocrystal Amphotericin B, against cryptococcal meningitis in HIV-positive individuals. The treatment demonstrated improved survival rates and reduced toxicity compared to conventional intravenous amphotericin B.
A new study published in BMJ Oncology has found that relatively short-term use of immunosuppressant medications to control inflammatory diseases is not associated with an increased risk of developing cancer. The research included over 10,000 participants and tracked their cancer incidence for an average of 10 years.
Public health experts recommend continuing routine mask-wearing in healthcare settings to protect vulnerable patients and staff from COVID-19. The authors argue that while severe cases have decreased, asymptomatic spread remains a threat, particularly among high-risk patients and healthcare workers who may not be aware they are infected.
A new study found that a simple blood test can predict the risk of progressive heart and kidney disease in people with Type 2 diabetes. The test measures levels of four biomarkers, which fell after treatment with canagliflozin, a type 2 diabetes medicine.
Researchers at the University of Tokyo have developed a DNA-based anticoagulant that has shown promising results in test mice and may be ready for human trials soon. The treatment could provide a safer alternative to existing medications, such as heparin, which can cause severe bleeding side effects.
Rutgers scientists have devised a highly accurate method for creating coatings of biologically active materials, achieving efficiencies statistically indistinguishable from 100 percent. This breakthrough could make electrospray deposition more appealing for the manufacture of medical devices using bioactive materials.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
A long-term study of nearly 2,400 solid organ transplant recipients found that COVID-19 vaccination significantly reduced hospitalization rates, with a 75% decrease in later omicron waves. Despite this, post-vaccination SARS-CoV-2 viral infections remain common, highlighting the importance of vaccination in high-risk populations.
The FDA approved brexpiprazole, an antipsychotic drug, for treating agitation in elderly patients with dementia, despite trials showing it failed to provide a clinically meaningful benefit and increased the risk of death. The decision may reverse efforts to reduce off-label use of antipsychotics in care homes.
Researchers at Michigan Medicine have discovered a potential treatment for diffuse midline glioma, a type of childhood brain tumor with no effective treatments. The compound ONC201 nearly doubled survival rates in patients with the disease, and the underlying mechanism behind its success has been explained.
A study by the University of Gothenburg found that many expensive cancer drugs have unclear patient benefits, with only one drug showing both increased life expectancy and improved quality of life. The researchers emphasize the need for further discussions on drug approvals to ensure effective use of limited healthcare resources.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
A new drug treatment, KCL-286, has demonstrated safety and tolerability in a Phase 1 clinical trial, promoting recovery through activating retinoic acid receptor beta (RARb) in the spine. Researchers are now seeking funding for a Phase 2a trial to study its effects in those with spinal cord injuries.
A new study demonstrates that a pill inhibiting a gut enzyme can protect mice from IBD symptoms and preserve intestinal barrier function. The experimental GCPII-inhibiting drug was shown to improve stool consistency, reduce rectal bleeding and inflammation, with no apparent side effects.
LSU Health researchers found combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases effectiveness in experimental models of ER+ and TNBC. The study's findings suggest a new approach for treating treatment-resistant breast cancers.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
A large study found that fully vaccinated individuals have lower concentrations of inflammatory markers than unvaccinated participants after symptomatic COVID-19 infection. This suggests that vaccination significantly reduces morbidity and mortality by reducing elevated levels of cytokines and chemokines.